Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | DNM1 | Q05193 | 7/20 | 0.38 |
| ▸ | CES2 | O00748 | 3/20 | 0.36 |
| ▸ | CES1 | P23141 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10866350 | 1.00 | TSHR (0.44) | TSHRTHRBDNM1CES2CES1 | |
| SCHEMBL902302 | 1.00 | TSHR (0.44) | TSHRTHRBDNM1CES2CES1 | |
| SCHEMBL11192942 | 1.00 | TSHR (0.44) | TSHRTHRBDNM1CES2CES1 | |
| SCHEMBL6662074 | 1.00 | TSHR (0.44) | TSHRTHRBDNM1CES2CES1 | |
| SCHEMBL11880617 | 1.00 | TSHR (0.44) | TSHRTHRBDNM1CES2CES1 | |
| SCHEMBL25599070 | 1.00 | TSHR (0.44) | TSHRTHRBDNM1CES2CES1 | |
| SCHEMBL30846998 | 1.00 | TSHR (0.44) | TSHRTHRBDNM1CES2CES1 | |
| SCHEMBL5424877 | 1.00 | TSHR (0.44) | TSHRTHRBDNM1CES2CES1 | |
| SCHEMBL3371704 | 0.97 | — | — | |
| SCHEMBL17817329 | 0.95 | TSHR (0.40) | TSHRTHRBDNM1CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0612525-B1 | Transdermal treatment with mast cell degranulating agents for drug-induced hypersensitivity | BRISTOL MYERS SQUIBB CO (US) | 2001-09-19 | — | — | EP | claimed |
| EP-0612525-A1 | Transdermal treatment with mast cell degranulating agents for drug-induced hypersensitivity | BRISTOL-MYERS SQUIBB COMPANY (US) | 1994-08-31 | — | — | EP | claimed |
| CN-117396223-A | Methods of treating nonalcoholic steatohepatitis using SCD-1 inhibitors | 利皮迪奥制药公司 | 2024-01-12 | — | — | CN | disclosed |
| WO-2014123977-A1 | GERANYLGERANYLACETONE FORMULATIONS | ROHTO USA, INC. (US) | 2014-08-14 | — | — | WO | disclosed |
| US-20130273138-A1 | TRANSDERMAL FORMULATIONS OF GERANYLGERANYLACETONE | COYOTE PHARMACEUTICALS, INC. | 2013-10-17 | — | — | US | disclosed |
| WO-2013130648-A1 | TRANSDERMAL FORMULATIONS OF GERANYLGERANYLACETONE | COYOTE PHARMACEUTICALS, INC. (US) | 2013-09-06 | — | — | WO | disclosed |
| EP-0754006-A4 | METHOD AND APPARATUS FOR DIAGNOSING ERECTILE DYSFUNCTION | VIVUS INC (US) | 1998-08-19 | — | — | EP | disclosed |
| EP-0841896-A1 | REVERSE GELS COMPRISING A CONTINUOUS FLUORINATED PHASE | ALLIANCE PHARMACEUTICAL CORPORATION (US) | 1998-05-20 | — | — | EP | disclosed |
| WO-1997003644-A1 | REVERSE GELS COMPRISING A CONTINUOUS FLUORINATED PHASE | ALLIANCE PHARMACEUTICAL CORP. (US) | 1997-02-06 | — | — | WO | disclosed |
| EP-0754006-A1 | METHOD AND APPARATUS FOR DIAGNOSING ERECTILE DYSFUNCTION | Vivus, Inc. (US) | 1997-01-22 | — | — | EP | disclosed |
| WO-1995026158-A1 | METHOD AND APPARATUS FOR DIAGNOSING ERECTILE DYSFUNCTION | VIVUS, INC. (US) | 1995-10-05 | — | — | WO | disclosed |
| EP-0591432-A4 | SOLUBILITY PARAMETER BASED DRUG DELIVERY SYSTEM AND METHOD FOR ALTERING DRUG SATURATION CONCENTRATION. | NOVEN PHARMA (US) | 1995-05-17 | — | — | EP | disclosed |
| EP-0379045-B1 | Transdermal acrylic multipolymer drug delivery system | NOVEN PHARMA (US) | 1995-05-10 | — | — | EP | disclosed |
| EP-0591432-A1 | SOLUBILITY PARAMETER BASED DRUG DELIVERY SYSTEM AND METHOD FOR ALTERING DRUG SATURATION CONCENTRATION | NOVEN PHARMACEUTICALS, INC. (US) | 1994-04-13 | — | — | EP | disclosed |
| US-4086079-A | FOR FRUIT BEARING PLANTS | THE PROCTER & GAMBLE COMPANY (US) | 1978-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130273138-A1 | TRANSDERMAL FORMULATIONS OF GERANYLGERANYLACETONE | GAP43, GGPS1, FNTA | TSHR 3280/4885THRB 1033/4885DNM1 2908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.